{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:14:58Z","timestamp":1778253298854,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rmr.2025.12.061","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:37:22Z","timestamp":1774355842000},"page":"34-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Les indications et modalit\u00e9s des traitements non usuels sous forme inhal\u00e9e dans les pathologies respiratoires\u00a0: une revue narrative"],"prefix":"10.1016","volume":"43","author":[{"given":"L.","family":"Frisson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Reychler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.rmr.2025.12.061_bib0395","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1513\/AnnalsATS.201806-368AW","article-title":"Emerging concepts and therapies for mucoobstructive lung disease","volume":"15","author":"Mall","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.rmr.2025.12.061_bib0400","first-page":"318","article-title":"An 8-year follow-up of FEV and respiratory symptoms in middle-aged men [proceedings]","volume":"57","author":"Fletcher","year":"1976","journal-title":"Scand J Respir Dis"},{"key":"10.1016\/j.rmr.2025.12.061_bib0405","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1164\/ajrccm.153.5.8630597","article-title":"Association of chronic mucus hypersecretion with FEV1\u00a0decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group","volume":"153","author":"Vestbo","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0410","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2023.2065","article-title":"Airway-occluding mucus plugs and mortality in patients with chronic obstructive pulmonary disease","volume":"329","author":"Diaz","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2025.12.061_bib0415","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.chest.2023.11.033","article-title":"Silent airway mucus plugs in COPD and clinical implications","volume":"166","author":"Mettler","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0420","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1177\/002013240004500711","article-title":"Evaluating the efficacy of mucoactive aerosol therapy","volume":"45","author":"Fuloria","year":"2000","journal-title":"Respir Care"},{"key":"10.1016\/j.rmr.2025.12.061_bib0425","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMra0910061","article-title":"Airway mucus function and dysfunction","volume":"363","author":"Fahy","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0430","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619866102","article-title":"Nebulized hypertonic saline in noncystic fibrosis bronchiectasis: a comprehensive review","volume":"13","author":"M\u00e1iz Carro","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"6\u00a0Pt 1","key":"10.1016\/j.rmr.2025.12.061_bib0435","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1164\/ajrccm.157.6.9706036","article-title":"Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile","volume":"157","author":"Zahm","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0440","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1183\/09031936.95.08030381","article-title":"Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus","volume":"8","author":"Zahm","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.12.061_bib0445","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1586\/14737167.4.1.49","article-title":"Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis","volume":"4","author":"Zijlstra","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.rmr.2025.12.061_bib0450","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"issue":"2\u00a0Pt 1","key":"10.1016\/j.rmr.2025.12.061_bib0455","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1164\/ajrccm.154.2.8756815","article-title":"Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability","volume":"154","author":"Wills","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0460","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1378\/chest.113.5.1329","article-title":"Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group","volume":"113","author":"O\u2019Donnell","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0465","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1152\/physrev.00004.2021","article-title":"Physiology and pathophysiology of human airway mucus","volume":"102","author":"Hill","year":"2022","journal-title":"Physiol Rev"},{"key":"10.1016\/j.rmr.2025.12.061_bib0470","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.rmed.2012.04.002","article-title":"The use of rhDNAse in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study","volume":"106","author":"Silverman","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0475","first-page":"CD001289","article-title":"Mucolytics for bronchiectasis","volume":"2014","author":"Wilkinson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2025.12.061_bib0480","first-page":"1141","article-title":"Application of N-acetylcysteine inhalation in treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease","volume":"6","author":"Ren","year":"2019","journal-title":"J Jilin University"},{"key":"10.1016\/j.rmr.2025.12.061_bib0485","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1378\/chest.54.6.504","article-title":"Nebulization of N-acetylcysteine combined with a bronchodilator in patients with chronic bronchitis. A controlled study","volume":"54","author":"Kory","year":"1968","journal-title":"Dis Chest"},{"issue":"Suppl. 1","key":"10.1016\/j.rmr.2025.12.061_bib0490","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guideline for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"Suppl. 1","key":"10.1016\/j.rmr.2025.12.061_bib0495","first-page":"1","article-title":"British Thoracic Society Guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2025.12.061_bib0500","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rmed.2004.05.006","article-title":"Evaluation of nebulised hypertonic saline (7\u00a0%) as an adjunct to physiotherapy in patients with stable bronchiectasis","volume":"99","author":"Kellett","year":"2005","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0510","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2011.12.021","article-title":"The long term effect of inhaled hypertonic saline 6\u00a0% in non-cystic fibrosis bronchiectasis","volume":"106","author":"Nicolson","year":"2012","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0515","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jamp.2017.1443","article-title":"Impact of hypertonic saline solutions on sputum expectoration and their safety profile in patients with bronchiectasis: a randomized crossover trial","volume":"31","author":"Herrero-Cortina","year":"2018","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.rmr.2025.12.061_bib0520","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7\u00a0% hypertonic saline improves lung function and quality of life in bronchiectasis","volume":"105","author":"Kellett","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0505","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/resp.13047","article-title":"Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis","volume":"22","author":"Tarrant","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.rmr.2025.12.061_bib0525","doi-asserted-by":"crossref","first-page":"230178","DOI":"10.1183\/16000617.0178-2023","article-title":"Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis","volume":"33","author":"Concei\u00e7\u00e3o","year":"2024","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.rmr.2025.12.061_bib0530","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chest.2024.01.045","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: updated systematic review and meta-analysis","volume":"166","author":"Cordeiro","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0535","doi-asserted-by":"crossref","first-page":"106283","DOI":"10.1016\/j.rmed.2020.106283","article-title":"Inhaled tobramycin for chronic infection with Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis","volume":"176","author":"Sangiovanni","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0540","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJM199104183241602","article-title":"A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia","volume":"324","author":"Hirschel","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0545","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1177\/09564624241245155","article-title":"Nebulised pentamidine prophylaxis of pneumocystis pneumonia in adults accessing HIV services at royal free hospital, London","volume":"35","author":"Bergstrom","year":"2024","journal-title":"Int J STD AIDS"},{"issue":"Suppl. 2","key":"10.1016\/j.rmr.2025.12.061_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00944_1.x","article-title":"British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011","volume":"12","author":"Nelson","year":"2011","journal-title":"HIV Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0555","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1183\/09031936.96.09051006","article-title":"Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia","volume":"9","author":"Ewig","year":"1996","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.12.061_bib0560","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1378\/chest.98.4.907","article-title":"Acute pulmonary effects of aerosolized pentamidine. A randomized controlled study","volume":"98","author":"Chan","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0565","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(91)90600-3","article-title":"Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer","volume":"90","author":"Murphy","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0570","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1378\/chest.110.1.141","article-title":"An effectiveness community-based clinical trial of Respirgard II and Fisoneb nebulizers for Pneumocystis carinii prophylaxis with aerosol pentamidine in HIV-infected individuals. Toronto Aerosol Pentamidine Study (TAPS) Group","volume":"110","author":"McIvor","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0575","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1378\/chest.123.6.1983","article-title":"The pulmonary effects of long-term exposure to aerosol pentamidine: a 5-year surveillance study in HIV-infected patients","volume":"123","author":"Obaji","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0580","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/jpm.2014.0126","article-title":"Nebulized morphine for intractable cough in advanced cancer: two case reports","volume":"18","author":"An","year":"2015","journal-title":"J Palliat Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0585","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00000446-200205001-00004","article-title":"Nebulized morphine for terminal dyspnea: a treatment option in chronic obstructive pulmonary disease or end-stage congestive heart failure","volume":"102\u00a0Suppl","author":"Westphal","year":"2002","journal-title":"Am J Nurs"},{"key":"10.1016\/j.rmr.2025.12.061_bib0590","doi-asserted-by":"crossref","first-page":"e28637","DOI":"10.1097\/MD.0000000000028637","article-title":"Nebulized fentanyl for respiratory symptoms in patients with COVID-19 (ventanyl trial)","volume":"101","author":"Shaikh","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rmr.2025.12.061_bib0595","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jjco\/29.12.600","article-title":"Effect of nebulized morphine in cancer patients with dyspnea: a pilot study","volume":"29","author":"Tanaka","year":"1999","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.rmr.2025.12.061_bib0600","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/026921639701100402","article-title":"Nebulized morphine in the palliation of dyspnoea","volume":"11","author":"Zeppetella","year":"1997","journal-title":"Palliat Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0605","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1183\/09031936.97.10051079","article-title":"Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine","volume":"10","author":"Noseda","year":"1997","journal-title":"Eur Respir J"},{"issue":"6\u00a0Pt 1","key":"10.1016\/j.rmr.2025.12.061_bib0610","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1164\/ajrccm.152.6.8520759","article-title":"Low-dose nebulized morphine does not improve exercise in interstitial lung disease","volume":"152","author":"Harris-Eze","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0615","doi-asserted-by":"crossref","first-page":"101938","DOI":"10.1016\/j.pupt.2020.101938","article-title":"Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis","volume":"63","author":"Surber","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2025.12.061_bib0620","doi-asserted-by":"crossref","first-page":"e10401","DOI":"10.1002\/btm2.10401","article-title":"Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis","volume":"8","author":"Andrade da Silva","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0625","doi-asserted-by":"crossref","first-page":"101933","DOI":"10.1016\/j.pupt.2020.101933","article-title":"Inhalation: A means to explore and optimize nintedanib's pharmacokinetic\/pharmacodynamic relationship","volume":"63","author":"Epstein-Shochet","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2025.12.061_bib0635","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12931-018-0886-9","article-title":"Inhaled furosemide for relief of air hunger versus sense of breathing effort: a randomized controlled trial","volume":"19","author":"Grogono","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.rmr.2025.12.061_bib0640","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/pupt.2002.0376","article-title":"Effects of inhaled furosemide on CO(2) ventilatory responsiveness in humans","volume":"15","author":"Minowa","year":"2002","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.rmr.2025.12.061_bib0645","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.resp.2017.10.002","article-title":"Aerosol furosemide for dyspnea: controlled delivery does not improve effectiveness","volume":"247","author":"Mor\u00e9lot-Panzini","year":"2018","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.rmr.2025.12.061_bib0650","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00045391-200207000-00009","article-title":"Furosemide: progress in understanding its diuretic, anti-inflammatory, and bronchodilating mechanism of action, and use in the treatment of respiratory tract diseases","volume":"9","author":"Prandota","year":"2002","journal-title":"Am J Ther"},{"key":"10.1016\/j.rmr.2025.12.061_bib0655","first-page":"300","article-title":"Prevention of exercise-induced asthma in children using low doses of inhaled furosemide","volume":"3","author":"Roger","year":"1993","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.rmr.2025.12.061_bib0660","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0091-6749(97)70097-6","article-title":"Comparative efficacy of inhaled furosemide and disodium cromoglycate in the treatment of exercise-induced asthma in children","volume":"99","author":"Melo","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"6\u00a0Pt 1","key":"10.1016\/j.rmr.2025.12.061_bib0665","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0091-6749(95)70227-X","article-title":"The preventive effect and duration of action of two doses of inhaled furosemide on exercise-induced asthma in children","volume":"96","author":"Novembre","year":"1995","journal-title":"J Allergy Clin Immunol"},{"issue":"2\u00a0Pt 1","key":"10.1016\/j.rmr.2025.12.061_bib0670","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/ai.1994.v94.a54941","article-title":"The preventive effect of nedocromil or furosemide alone or in combination on exercise-induced asthma in children","volume":"94","author":"Novembre","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.rmr.2025.12.061_bib0675","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1378\/chest.106.5.1396","article-title":"Inhaled furosemide is not effective in acute asthma","volume":"106","author":"Karpel","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2025.12.061_bib0680","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/thx.2007.091538","article-title":"Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer","volume":"63","author":"Wilcock","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2025.12.061_bib0685","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0885-3924(01)00367-0","article-title":"Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients","volume":"23","author":"Shimoyama","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.rmr.2025.12.061_bib0690","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/026921639400800315","article-title":"Nebulized frusemide for dyspnoea","volume":"8","author":"Stone","year":"1994","journal-title":"Palliat Med"},{"key":"10.1016\/j.rmr.2025.12.061_bib0695","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0885-3924(03)00322-1","article-title":"Effect of nebulized furosemide in terminally ill cancer patients with dyspnea","volume":"26","author":"Kohara","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.rmr.2025.12.061_bib0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2014.1136","article-title":"Nebulized medications for the treatment of dyspnea: a literature review","volume":"28","author":"Boyden","year":"2015","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.rmr.2025.12.061_bib0705","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/17425247.2022.2084530","article-title":"Inhaled antifungal therapy: benefits, challenges, and clinical applications","volume":"19","author":"Ito","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.rmr.2025.12.061_bib0710","doi-asserted-by":"crossref","first-page":"e00690","DOI":"10.1002\/prp2.690","article-title":"Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent","volume":"9","author":"Cass","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.rmr.2025.12.061_bib0715","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/pharmaceutics14030641","article-title":"Inhaled antifungal agents for treatment and prophylaxis of bronchopulmonary invasive mold infections","volume":"14","author":"Brunet","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.rmr.2025.12.061_bib0720","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/myc.12294","article-title":"Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review","volume":"58","author":"Godet","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.rmr.2025.12.061_bib0725","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/myc.13591","article-title":"Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): results of an open-label randomized controlled trial","volume":"66","author":"Muthu","year":"2023","journal-title":"Mycoses"},{"key":"10.1016\/j.rmr.2025.12.061_bib0730","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.healun.2016.01.007","article-title":"The 2015\u00a0International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary","volume":"35","author":"Husain","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.rmr.2025.12.061_bib0735","doi-asserted-by":"crossref","first-page":"e13544","DOI":"10.1111\/ctr.13544","article-title":"Invasive Aspergillosis in solid-organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Husain","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.rmr.2025.12.061_bib0740","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016\u00a0update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2025.12.061_bib0745","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1016\/j.transproceed.2008.09.020","article-title":"Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation","volume":"40","author":"Borro","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.rmr.2025.12.061_bib0750","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.rmr.2025.12.061_bib0755","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01697981","article-title":"Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients","volume":"71","author":"Behre","year":"1995","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rmr.2025.12.061_bib0760","first-page":"3654","article-title":"Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial","volume":"93","author":"Schwartz","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.rmr.2025.12.061_bib0765","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12281-010-0011-0","article-title":"Aerosolized delivery of antifungal agents","volume":"4","author":"Le","year":"2010","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.rmr.2025.12.061_bib0770","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.TP.0000101516.08327.A9","article-title":"Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients","volume":"77","author":"Drew","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.rmr.2025.12.061_bib0775","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1183\/09031936.00163511","article-title":"Remarkably efficient inhaled antifungal monotherapy for invasive pulmonary aspergillosis","volume":"40","author":"Hilberg","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2025.12.061_bib0390","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1097\/TP.0000000000002697","article-title":"Aerosolization of second-generation triazoles: in vitro evaluation and application in therapy of invasive airway aspergillosis","volume":"103","author":"Thanukrishnan","year":"2019","journal-title":"Transplantation"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842526000069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:57:35Z","timestamp":1778252255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842526000069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0761842526000069"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2025.12.061","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les indications et modalit\u00e9s des traitements non usuels sous forme inhal\u00e9e dans les pathologies respiratoires\u00a0: une revue narrative","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2025.12.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SPLF. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}